Kitra Nichols
Family · Columbia, SCNPI 1467893891
Payments from drug & device makers
Across 436 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$913
- AstraZeneca$678
- Johnson & Johnson$671
- Merck$552
- Pfizer$392
- Lilly USA, LLC$360
- plus $6K from 54 others
What the payments were for
- Food & beverage$9,131100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,131 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 74 | $1,210,034 |
| PromactaEltrombopag Olamine | 33 | $666,410 |
| BrukinsaZanubrutinib | 42 | $612,777 |
| PomalystPomalidomide | 23 | $539,287 |
| RevlimidLenalidomide | 30 | $498,927 |
| XtandiEnzalutamide | 34 | $466,374 |
| IbrancePalbociclib | 19 | $300,785 |
| ErleadaApalutamide | 18 | $263,414 |
| TasignaNilotinib Hcl | 13 | $249,229 |
| AlecensaAlectinib Hcl | 12 | $225,581 |
| Abiraterone Acetate | 94 | $171,446 |
| Lenalidomide | 11 | $157,914 |
| Imatinib Mesylate | 23 | $60,264 |
| CreonLipase/Protease/Amylase | 17 | $25,536 |
| EliquisApixaban | 26 | $14,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $15 | $1,210,03474 claims |
| NovartisPromacta, Tasigna | $913 | $915,63946 claims |
| Beigene USA, Inc.Brukinsa | $65 | $612,77742 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $72 | $539,28723 claims |
| Bristol Myers SquibbRevlimid | $296 | $498,92730 claims |
| Astellas Pharma US IncXtandi | $179 | $466,37434 claims |
| PfizerIbrance, Eliquis | $392 | $315,33245 claims |
| Johnson & JohnsonErleada | $671 | $263,41418 claims |
| Genentech USA, Inc.Alecensa | $279 | $225,58112 claims |
| AbbVieCreon | $105 | $25,53617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Columbia
- Mary WilliamsColumbia$67K
- Devon DriverColumbia$21K
- Amanda CharltonColumbia$15K
- Katherine ColemanColumbia$15K
- Melissa RedmondColumbia$13K
- Andrew FieldsColumbia$12K
- Jodi MyersColumbia$12K
- Alaina McClerklinColumbia$11K
- Coty CampbellColumbia$11K
- Patricia DaileyColumbia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.